Sanz-Rodriguez C, Gil-Fernández J J, Zapater P, Pinilla I, Granados E, Gómez-G de Soria V, Cano J, Sala N, Fernández-Rañada J M, Gómez-Gómez N
Department of Hematology, Hospital Universitario de la Princesa, Madrid, Spain.
Thromb Haemost. 1999 Jun;81(6):887-90.
We present the case of a full-term newborn in whom purpura fulminans developed shortly after birth. A diagnosis of homozygous protein C deficiency was established based upon undetectable plasma protein C activity and antigenemia in the newborn infant, and was later confirmed by protein C gene analysis. Specific replacement therapy with intravenous protein C concentrate was started 9 days after birth. This rapidly led to the complete regression of cutaneous lesions and consumption coagulopathy. After stabilization, oral anticoagulation was initiated in association with prophylactic treatment with intravenous protein C concentrate. However, oral anticoagulation was finally abandoned as the patient presented several thrombotic and hemorrhagic episodes clearly related to difficulties with anticoagulation. Due to the hazards related to prolonged venous access, we are currently using subcutaneous infusion of protein C concentrate for the long-term management of this condition, with satisfactory results.
我们报告一例足月新生儿,其出生后不久即发生暴发性紫癜。根据新生儿血浆蛋白C活性及抗原血症检测不到,诊断为纯合子蛋白C缺乏症,随后通过蛋白C基因分析得以证实。出生9天后开始静脉输注蛋白C浓缩物进行特异性替代治疗。这迅速导致皮肤病变和消耗性凝血病完全消退。病情稳定后,开始口服抗凝治疗并联合静脉输注蛋白C浓缩物进行预防性治疗。然而,由于患者出现了几次明显与抗凝困难相关的血栓形成和出血发作,最终放弃了口服抗凝治疗。由于长期静脉通路存在风险,我们目前正在使用皮下输注蛋白C浓缩物对该疾病进行长期管理,效果令人满意。